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Accelerated accumulation of retinal α-synuclein (pSer129) and tau,
neuroinflammation, and autophagic dysregulation in a seeded mouse
model of Parkinson's disease
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by accumulation of misfolded α-
synuclein within the central nervous system (CNS). Visual problems in PD patients are common, although
retinal pathology associated with PD is not well understood. The purpose of this study was to investigate
retinal pathology in a transgenic mouse model (TgM83) expressing the human A53T α-synuclein mutation
and assess the effect of α-synuclein “seeding” on the development of retinal pathology. Two-month-old
TgM83 mice were intracerebrally inoculated with brain homogenate from old (12–18 months) TgM83 mice.
Retinas were then analyzed at 5 months of age. We analyzed retinas from 5-month-old and 8-month-old
uninoculated healthy TgM83 mice, and old (12–18 months) mice that were euthanized following the
development of clinical signs. Retinas of B6C3H mice (genetic background of the TgM83 mouse) served as
control. We used immunohistochemistry and western blot analysis to detect accumulation of α-synuclein,
pTauThr231, inflammation, changes in macroautophagy, and cell death. Raman spectroscopy was used to test
the potential to differentiate between retinal tissues of healthy mice and diseased mice. This work
demonstrates retinal changes associated with the A53T mutation. Retinas of non-inoculated TgM83 mice had
accumulation of α-synuclein, “pre-tangle” tau, activation of retinal glial cells, and photoreceptor cell loss by 8
months of age. The development of these changes is accelerated by inoculation with brain homogenate from
clinically ill TgM83 mice. Compared to non-inoculated 5-month-old TgM83 mice, retinas of inoculated
5-month-old mice had increased accumulation of α-synuclein (pSer129) and pTauThr231 proteins,
upregulated microglial activation, and dysregulated macroautophagy. Raman spectroscopic analysis was able
to discriminate between healthy and diseased mice. This study describes retinal pathology resulting from the
A53T mutation. We show that seeding with brain homogenates from old TgM83 mice accelerates retinal
pathology. We demonstrate that Raman spectroscopy can be used to accurately identify a diseased retina
based on its biochemical profile, and that α-synuclein accumulation may contribute to accumulation of
pTauThr231 proteins, neuroinflammation, metabolic dysregulation, and photoreceptor cell death. Our work
provides insight into retinal changes associated with Parkinson's disease, and may contribute to a better
understanding of visual symptoms experienced by patients.
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A B S T R A C T
Parkinson's disease (PD) is a neurodegenerative disorder characterized by accumulation of misfolded α-synu-
clein within the central nervous system (CNS). Visual problems in PD patients are common, although retinal
pathology associated with PD is not well understood. The purpose of this study was to investigate retinal pa-
thology in a transgenic mouse model (TgM83) expressing the human A53T α-synuclein mutation and assess the
eﬀect of α-synuclein “seeding” on the development of retinal pathology. Two-month-old TgM83 mice were
intracerebrally inoculated with brain homogenate from old (12–18months) TgM83 mice. Retinas were then
analyzed at 5months of age. We analyzed retinas from 5-month-old and 8-month-old uninoculated healthy
TgM83 mice, and old (12–18months) mice that were euthanized following the development of clinical signs.
Retinas of B6C3H mice (genetic background of the TgM83 mouse) served as control. We used im-
munohistochemistry and western blot analysis to detect accumulation of α-synuclein, pTauThr231, inﬂammation,
changes in macroautophagy, and cell death. Raman spectroscopy was used to test the potential to diﬀerentiate
between retinal tissues of healthy mice and diseased mice. This work demonstrates retinal changes associated
with the A53T mutation. Retinas of non-inoculated TgM83 mice had accumulation of α-synuclein, “pre-tangle”
tau, activation of retinal glial cells, and photoreceptor cell loss by 8months of age. The development of these
changes is accelerated by inoculation with brain homogenate from clinically ill TgM83 mice. Compared to non-
inoculated 5-month-old TgM83 mice, retinas of inoculated 5-month-old mice had increased accumulation of α-
synuclein (pSer129) and pTauThr231 proteins, upregulated microglial activation, and dysregulated macro-
autophagy. Raman spectroscopic analysis was able to discriminate between healthy and diseased mice. This
study describes retinal pathology resulting from the A53T mutation. We show that seeding with brain homo-
genates from old TgM83 mice accelerates retinal pathology. We demonstrate that Raman spectroscopy can be
used to accurately identify a diseased retina based on its biochemical proﬁle, and that α-synuclein accumulation
may contribute to accumulation of pTauThr231 proteins, neuroinﬂammation, metabolic dysregulation, and
photoreceptor cell death. Our work provides insight into retinal changes associated with Parkinson's disease, and
may contribute to a better understanding of visual symptoms experienced by patients.
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List of abbreviations
PD Parkinson's Disease
CNS Central nervous system
SNpc substantia nigra pars compacta
TH Tyrosine hydroxylase
MSA multiple system atrophy
PSP progressive supranuclear palsy
AD Alzheimer's Disease
CMA chaperone-mediated autophagy
TSEs transmissible spongiform encephalopathies
GCL ganglion cell layer
INL inner nuclear layer
IPL inner plexiform layer
OPL outer plexiform layer
ONL outer nuclear layer
1. Introduction
Parkinson's disease (PD) is a neurodegenerative disorder char-
acterized by two key disease processes: progressive degeneration of
dopaminergic neurons of the substantia nigra pars compacta (SNpc) in
the midbrain that leads to deﬁcits in voluntary movement, and the
accumulation of intraneuronal Lewy-bodies, containing misfolded α-
synuclein (Recasens and Dehay 2014). Prominent non-motor phe-
nomena, speciﬁcally visual disturbances, are a considerable cause of
morbidity in Parkinson's disease (Archibald et al. 2009; Armstrong
2011). There is evidence of visual dysfunction at several levels of the
visual pathway in patients with PD, including morphological and
electrophysiological indication of disruption of retinal structure and
function (Armstrong 2011; Bodis-Wollner 2013; Ridder et al. 2017).
However, the direct eﬀect of misfolded α-synuclein on the retina is not
well understood, and molecular biomarkers of PD progression in the
retina are lacking.
Here, we use the TgM83 mouse model to investigate retinal pa-
thology due to a human α-synuclein (A53T) gene mutation. We also use
this model to study the eﬀect of α-synuclein seeding in the brain, on
development of pathology in the retina. Often referred to as “prion-like
propagation”, the transport of misfolded proteins from one central
nervous system structure (CNS) seeds protein misfolding and propa-
gation in another (Angot et al. 2010; Greenlee et al. 2016; Luk et al.
2012a; Mougenot et al. 2012; Watts et al. 2013; Woerman et al. 2017).
This is consistent with the Braak staging of Parkinson's disease, which
describes a progressive and non-random process with speciﬁc neuronal
types giving rise to the development of Lewy pathology in a speciﬁc
pattern (i.e. caudo-rostral progression of disease from the lower
brainstem, followed by the midbrain, forebrain, and cerebral cortex)
and as disease progresses, lesion severity in vulnerable brain regions
increases (Braak et al. 2003). A growing body of in vitro and in vivo
evidence describes the ability of pathological α-synuclein to spread
transcellularly and induce aggregation by templating protein mis-
folding (Angot et al. 2010; Katorcha et al. 2017; Luk et al. 2012a; Luk
et al. 2012b; Mougenot et al. 2012; Woerman et al. 2017). An in vivo
study shows that seeding with an inoculum derived from the brain of
clinically ill mice, results in acceleration of α-synuclein-associated
disease and shortening of survival time (Mougenot et al. 2012). Disease
acceleration is associated with an insoluble form of α-synuclein phos-
phorylated on serine 129 (Mougenot et al. 2012). Among several ex-
isting post-translational modiﬁcations to α-synuclein known to occur in
PD, phosphorylation at Ser129 (herein referred to as pSer129), has been
reported to enhance α-synuclein toxicity both in vitro and in vivo (Chen
et al. 2009; Fujiwara et al. 2002; Smith et al. 2005). Although α-sy-
nuclein is not an infectious agent, studies attribute the enhanced toxi-
city of pSer129 to increased formation and self-propagation of α-
synuclein aggregates (Angot et al. 2010). In this study, we use a mouse
model of α-synuclein seeding to study the eﬀect of α-synuclein
spreading in the CNS, speciﬁcally on development and progression of
retinal pathology. Herein, we report the time course of speciﬁc retinal
changes associated with the A53T mutation, including: accumulation of
pSer129 and ‘pre-tangle tau protein in the retina, dysregulation of
macroautophagy in response to the increase in misfolded proteins, and
loss of photoreceptors. We demonstrate accelerated development of
pathologic biomarkers in mice inoculated with brain homogenate from
clinically ill TgM83 mice.
We also explored the use of Raman spectroscopy to identify disease-
speciﬁc molecular signatures in retinal tissues from α-synuclein A53T
mutant mice. Raman spectroscopy is a sensitive and nondestructive
technique that provides rapid biochemical characterization of tissues
for diverse applications (Wang et al. 2011). The Raman eﬀect occurs
when an incident monochromatic light, emitted by a laser, scatters
when it passes through a substance. The scattered light is inelastic,
meaning it contains additional frequencies that are diﬀerent than that
of the incident frequency. These frequencies (i.e. emitted photons) are
captured by a Raman spectrophotometer, and the resulting spectrum
reveals ﬁngerprint regions speciﬁc to molecules' chemical bonds and
conﬁgurations. Raman spectra collected from samples are used to train
and test a classiﬁer to accurately discriminate between diseased and
healthy tissues according to changes in their molecular structure. Sev-
eral neurodegenerative diseases result from misfolding and accumula-
tion of speciﬁc proteins (e.g. α-synuclein and tau in Parkinson's disease,
tau and beta-amyloid in Alzheimer's disease, and prion proteins in
transmissible spongiform encephalopathies) that change the chemical
composition of tissues. Here, Raman spectroscopy was used to diﬀer-
entiate between the biochemical ﬁngerprints of retinal tissues from
healthy mice and mice with the α-synuclein A53T mutation. The clas-
siﬁer was able to discriminate between retinal tissues of control,
healthy, and diseased mice with high accuracy, even between samples
that appeared histologically similar.
To the best of our knowledge, this report is the ﬁrst to demonstrate
retinal pathology resulting from the A53T mutation, and that seeding
with brain homogenate from clinically ill mice accelerates retinal
pathology. This work implies a direct eﬀect of α-synuclein toxicity on
the retina, causing chronic neuroinﬂammation, metabolic dysregula-
tion and cell death. Additionally, this study describes the use of
Raman spectroscopic analysis for the diﬀerentiation of control retinas
and those aﬀected by α-synuclein associated pathology, with high
speciﬁcity. Here, we describe an in vivo model that provides insight
into how Parkinson's disease aﬀects the retina, and how α-synuclein
related changes may contribute to visual disturbances experienced by
patients.
2. Methods
2.1. Animals
Retinal tissues were provided by Thierry Baron (Anses, Laboratoire
de Lyon, Unité Maladies Neurodégénératives, Lyon, France). Brieﬂy, 2-
month-old homozygous TgM83 mice were subjected to intracerebral
ventricular inoculation (ICV) with 20 μL of 1% (wt/vol in glucose 5%)
brain homogenates obtained from half of the brain of clinically ill
TgM83 mice (12–18months), and euthanized three months after IC
inoculation, corresponding to a pre-clinical stage (Mougenot et al.
2012). Clinically-ill TgM83 mice were euthanized following the de-
velopment of motor clinical signs of disease, in this case paralysis of the
hind limbs. Care and housing of mice, as well as ethical approval is
described as per Mougenot et al., 2011. Eye globes were postﬁxed in
Bouin's ﬁxative for 24 h, embedded in paraﬃn, and sectioned sagitally
at 4-μm onto superfrost plus glass slides. We analyzed retinas of
homozygous TgM83 mice at 5, 8 (clinical illness), and 12–18 (clinical
illness) months of age; inoculated TgM83 mice at 5months of age; and
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B6C3H mice (genetic background of the TgM83 mouse model) at 5 and
8months of age (Fig. 1).
2.2. Immunohistochemistry
Paraﬃn-embedded sections (4 μm) of the retina were rehydrated
using xylene, followed by a decreasing ethanol concentration gradient
(100%, 90% 70%), and a ﬁnal wash with diH2O. Heat-mediated antigen
retrieval was performed using EDTA buﬀer (10mM Trizma Base, 1 mM
EDTA solution, 0.05% Tween 20, pH 9.0), or Citrate buﬀer (ScyTek
Laboratories, Logan, UT) in an autoclave for 30min. Tissues were in-
cubated with Background Buster (Innovex Biosciences Inc., Richmond,
CA) for 2 h. Primary antibodies against α-synuclein (1:1000, BD
Biosciences, San Jose, CA, 610786), α-synuclein p129S (1:500; Abcam,
Cambridge, MA, ab51253), tyrosine hydroxylase (1:50, Santa Cruz
Biotechnology, Dallas, TX), glial ﬁbrillary acidic protein (GFAP; 1:500;
Dako, Carpinteria, CA), CD11b (1:500; Abcam), CD68 (1:100; Abnova,
Taiwan), PHF-Tau Clone AT-180 (1:100; Thermo Fisher Scientiﬁc, Inc.,
Rockford, IL), calbindin (1:2000, Swant, Inc., Switzerland), LC3
(1:1000, Cell Signaling, Danvers, Massachusetts), or caspase-3 (1:50,
Santa Cruz Biotechnology) were diluted in blocking solution containing
0.1% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO),
0.05% Triton X-100 (Thermo Fisher Scientiﬁc, Inc., Rockford, IL) and
5% normal serum (Jackson ImmunoResearch, West Grove, PA) in Tris-
Buﬀered saline (TBS), and incubated for 48 h at room temperature.
Tissues were washed with TBS-T (6× 5min) and incubated with a
secondary antibody cocktail, including Cy™3 and/or Alexa Fluor
488–conjugated AﬃniPure secondary antibodies (1:250; Jackson
ImmunoResearch) and 40,6-diamidino-2phenylindole, dilactate (DAPI,
4 μg/mL; Sigma-Aldrich) for 1.5 h. Following another wash, slides were
mounted with Vectashield antifade mounting medium (Vector
Laboratories Inc., Burlingame, CA). Immunoreactivity for α-synuclein,
α-synuclein p129S, tyrosine hydroxylase, and Caspase-3 was developed
using Envision þ Dual Link System-horseradish peroxidase (Dako,
Carpinteria, CA) with diaminobenzidine (Vector Labs, Peterborough,
UK), and slides were counterstained with hematoxylin. Negative
controls were processed in parallel by omission of the primary and/or
secondary antibody.
2.3. Fluorescent microscopy and statistical analysis
Fluorescence and confocal images were taken at 20× and 60×,
using a Nikon A1R+ Resonant Scanning Confocal System with a Ti-E
inverted microscope and laser lines 405, 488, 561 and 640 nm (Nikon
Instruments Inc., Melville, New York). Micrographs were created using
a commercial photo-editing system (Adobe Photoshop and Adobe
Illustrator [CC]; Adobe Systems). For quantiﬁcation of GFAP, CD11b,
AT-180, and CD68 immunoreactivity, the percentage of the total image
area thresholded (outer limiting membrane to inner limiting membrane
of the retina) was analyzed using ImageJ (Rasband, W.S., ImageJ
1.49 V, U. S. National Institutes of Health, Bethesda, Maryland).
Quantiﬁed histological, and western blot data from three separate re-
plicates was analyzed using a two-way ANOVA, with a Tukey's multiple
comparisons test (post-hock). Thickness of the outer nuclear layer
(ONL) was measured by counting of cell bodies spanning the layer. For
each mouse, the central retina, near the optic disc, within a cross sec-
tion was used for analysis. Retinal thickness was analyzed using an
unpaired t-test. Prism 6 for Windows (Graph Pad Software) was used for
statistical analysis.
2.4. Protein extraction from paraﬃn embedded tissues for western blot
analysis
Bouin's ﬁxed paraﬃn-embedded sections (100 μm total, 10×10 μm
sections) of the retina were collected into 1.5mL microcentrifuge tubes.
Sections were deparaﬃnized and rehydrated using xylene, followed by
a decreasing ethanol concentration gradient (100%, 95% 70%). Then,
100 μL of lysis buﬀer containing protease and phosphatase inhibitor
cocktail was added to each sample, and samples were incubated on ice
for 5min. Samples were then incubated at 100 °C for 20min, then again
at 80 °C for 20min using a thermomixer with agitation (750 rpm).
Samples were then centrifuged for 15min (14,000 g at 4 °C).
Fig. 1. Experimental Design. Retinas of transgenic mice (TgM83) at 5, 8, and 12–18months of age, and age-matched controls (B6C3H) were analyzed using
immunohistochemistry and western blotting. Additionally, retinas of 2-month-old TgM83 mice were inoculated with brain homogenate from clinically ill (12–18-
month-old) TgM83 mice, and retinal tissues were analyzed 3months later.
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Supernatant was collected, and samples were kept overnight at−20 °C.
Tissues containing equal amounts of protein were separated on 4–20%
SDS-polyacrylamide gels. After separation, proteins were transferred to
polyvinylidene diﬂuoride (PVDF) membranes, and non-speciﬁc binding
sites were blocked by treating with 5% non-fat dry milk in 0.5% TBS-T
for 1 h. The membranes were then incubated with primary antibodies
directed against α-synuclein (1:5000, BD Biosciences, San Jose, CA), α-
synuclein p129S (1:1000; Abcam, Cambridge, MA), pAMPKT172
(1:1000, Cell Signaling, Danvers, Massachusetts), AMPK (1:1000, Cell
Signaling), pULK1S757 (1:1000, Cell Signaling), ULK1 (1:1000, Cell
Signaling), and LC3 (1:5000, Cell Signaling) overnight at 4 °C. The
primary antibody treatments were followed by treatment with HRP-
linked, anti-rabbit or anti-mouse secondary antibody (1:5000, Cell
Signaling) for 1 h at room temperature. Western blot images were
captured with the ChemiDoc™ XRS Imaging System (Bio-Rad), and
images were analyzed using Image Lab™ 6.0 Software (Bio-Rad). All
groups are normalized to 5-month-old B6C3H mice (genetic back-
ground of the TgM83 mouse model), providing a representative of a
fold-change from the control, therefore y-axis units are arbitrary.
2.5. Raman spectroscopy
Paraﬃn-embedded sections (4 μm) of the retina were placed on
gold‑aluminum coated microscope slides. Raman measurements were
performed using a DXR dispersive Raman microscope (Thermo
Scientiﬁc, Inc., Madison, Wisconsin) with a 532 nm, 14mW excitation
laser with 50 μm pinhole at ambient temperature and collected with a
20s exposure time from 110 to 3527 cm− 1 at a resolution of 1 cm – 1.
Retinal ganglion cells were resolved with a 60× objective. Twenty
spectra were collected from twenty diﬀerent retinal ganglion cells at
diﬀerent locations and an average spectrum was then calculated for
that cell to be used as one RGC spectrum in subsequent analysis (20
spectra from each retinal section, for a total of 400 spectra from each
group). Raman peaks that exhibited the most signiﬁcant changes be-
tween control and diseased tissue samples were identiﬁed. All spectra
were baseline corrected, smoothed, and normalized to reduce baseline
variability and background noise at the region between 110 and
3527 cm−1, using an iterative correction algorithm (Wang et al. 2011)
coded with R. After preprocessing, a principal component analysis
(PCA) was used to reduce dimensionality. Multi-class classiﬁcation was
generated using a support vector machine (SVM) (Gunn 1998). Cross-
validation was applied by randomly choosing 75% of the spectral data
to build the classiﬁcation model, using the remaining 25% of the
spectra to test and validate the classiﬁer. Average classiﬁcation accu-
racy was calculated from 10 random replications of the discriminant
process.
3. Results
3.1. Retinas of TgM83 mice exhibit α-synuclein accumulation
In Parkinson's disease, α-synuclein aggregates are highly enriched in
α-synuclein that has been phosphorylated at serine 129 (pSer129),
which has been reported to enhance the tendency of α-synuclein to
aggregate and disrupt normal function in vitro and in vivo (Walker
et al. 2013; Wang et al. 2012). To investigate whether α-synuclein
pSer129 is present in retinas of transgenic mice, we performed im-
munohistochemistry and western blot analysis. In addition to probing
for a speciﬁc pathogenic form of α-synuclein, we used im-
munohistochemistry and western blot analysis to determine levels and
pattern of total α-synuclein immunoreactivity in retinas of transgenic
mice. There was no pSer129 or total α-synuclein immunoreactivity
detected in control retinas (Fig. 2A, B). In retinas of all 5-month-old
transgenic mice, pSer129 immunoreactivity was evident only in the
outer nuclear layer (Fig. 2C). Compared to total α-synuclein, pSer129
immunoreactivity was sparse, with two to three patches of labeling per
retinal section of all mice (Fig. 2C, D). Retinas of inoculated 5-month-
old transgenic mice demonstrated upregulated pSer129 im-
munoreactivity, compared to 5-month-old non-inoculated mice
(Fig. 2C, E). In retinas of inoculated mice, pSer129 immunoreactivity
was detected throughout the outer segments of photoreceptor cells,
outer nuclear layer, outer plexiform layer, and inner nuclear layer,
demonstrating accelerated accumulation of α-synuclein in the seeded
model (Fig. 2C, E). Compared to control, retinas of 8-month-old and
clinically ill transgenic mice had α-synuclein labeling similar to that of
inoculated 5-month-old mice (Fig. 2G–L). In retinas of 8-month-old
mice, pSer129 immunoreactivity was only evident in the outer nuclear
layer, compared to total α-synuclein immunoreactivity that was also
present in the inner retina (Fig. 2I, J). Retinas of clinically ill mice had
similar distribution of pSer129 immunoreactivity throughout the outer
and inner retina (Fig. 2K, L). In all micrographs, p129S and total α-
synuclein immunoreactivity was more robust in the outer retina,
compared to the inner retina. Western blot analysis of p129S and total
α-synuclein protein levels produced similar results. Retinas of 8-month-
old, clinically ill, and inoculated 5-month-old mice, had signiﬁcantly
more α-synuclein (~2 fold compared to control and 5-month-old
transgenic mice; Fig. 2M, N). Our results indicated no signiﬁcant dif-
ference in pSer129 accumulation among 8-month-old transgenic,
clinically ill, or inoculated 5-month-old mice, suggesting that seeding of
α-synuclein from the brain to the retina results in accelerated accu-
mulation of the misfolded protein.
3.2. Activation of Müller glia in response to α-synuclein accumulation
To determine activation of Müller glia in response to misfolded
protein accumulation, we assessed the distribution of GFAP im-
munoreactivity using immunohistochemistry. Müller glia are the prin-
cipal glial component of the retina, responding to injury by increasing
GFAP expression in processes radially through the thickness of the re-
tina (Bringmann et al. 2006). GFAP immunoreactivity in retinas of
control mice was localized to the Müller glia end feet and astrocytes in
the optic ﬁber layer (Fig. 3A, D). Retinas of 5-month-old non-in-
oculated, and 5-month-old inoculated, and 8-month-old transgenic
mice had comparable GFAP immunoreactive processes spanning the
retina from the optic ﬁber layer to the outer plexiform layer (Fig. 3B, C,
E). Retinas of clinically ill mice had robust Müller glial activation with
hypertrophied Müller glia end feet, and GFAP immunoreactive pro-
cesses detectable in the outer nuclear layer (Fig. 3F). When quantiﬁed,
the area of GFAP immunoreactivity accounted for 13.99 ± 0.86%
(TgM83 5m), 13.32 ± 1.19% (inoculated TgM83 5m),
10.40 ± 1.21% (TgM83 8m), or 23.41 ± 2.17% (clinical TgM83 12-
18m) of total area (Fig. 3G). Activation of Müller glia was ﬁrst detected
in retinas of 5-month-old TgM83 mice and was signiﬁcantly increased
in retinas of 8-month-old and clinically ill mice. Compared to non-in-
oculated mice, retinas of 5-month-old inoculated mice did not have
increased GFAP, suggesting that α-synuclein seeding did not have a
detectable eﬀect on activation of Müller glia.
3.3. TgM83 mice exhibit pTauThr231 accumulation in retinal neurons and
Müller glia
To determine whether the α-synuclein (A53T) gene mutation leads
to accumulation of tau, an antibody against AT-180 (pThr231) was used
for an immunohistochemical analysis. Tau protein plays a critical role
in microtubule assembly, axonal transport, and neurite outgrowth, and
is a major component of neuroﬁbrillary tangles (NFTs) found in
Alzheimer's disease (AD) and Parkinson's disease (PD) (Lei et al. 2010).
Phosphorylated tau (pTauThr231) immunoreactivity was ﬁrst appreci-
able in retinas of 5-month-old transgenic mice, with no pTauThr231
immunoreactivity detected in retinas of corresponding control mice
(Fig. 4A, B). Compared to non-inoculated mice, retinas of 5-month-old
inoculated mice had greater pTauThr231 immunoreactivity (~7-fold
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higher), localized to the outer plexiform layer, ganglion cell layer, and
optic ﬁber layer (Fig. 4C, E). Compared to retinas of age-matched
control mice, those of 8-month-old transgenic mice had upregulated
pTauThr231 immunoreactivity (Fig. 4D, E), although signiﬁcantly less
than retinas of inoculated, and clinically ill transgenic mice (Fig. 4C, F).
When quantiﬁed, phosphorylated tau immunoreactivity comprised
1.11 ± 0.26% (TgM83 5m), 8.02 ± 0.82% (inoculated TgM83 5m),
2.63 ± 0.54% (TgM83 8m), or 6.71 ± 1.53% (clinical TgM83 12-
Fig. 3. Activation of Müller glia. (A, D) GFAP is localized to end feet of Müller glia in retinas of control mice. (B, C, E, F) Distribution of GFAP immunoreactivity is
increased, spanning the entire thickness of the retina. (G) Bar graphs show signiﬁcant increase in GFAP immunoreactivity in retinas of transgenic mice. Data are
expressed as mean ± SD. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear
layer. Scale bars: 20 μm. ****P < 0.0001 versus B6C3H (5m); +++P < 0.001 versus B6C3H (8m); ++++P < 0.0001 versus B6C3H (8m); ‡ ‡ ‡ ‡P < 0.0001.
Fig. 2. Accumulation of α-synuclein. (A, B) Retinas of B6C3H mice had no phospho-α-synuclein (p129S) immunoreactivity. (C-F) Retinas of transgenic mice showed
a similar trend, with sparse perinuclear and extracellular phospho α-synuclein (p129S) immunoreactivity at 5months of age, evident in the inner retina at the stage of
clinical disease. (E) Retinas of inoculated mice showed increased α-synuclein (p129S) immunoreactivity, localized to ONL as well as the inner retina. (G, H) Retinas
of B6C3H mice had no α-synuclein immunoreactivity. (I) Perinuclear and extracellular α-synuclein accumulation ﬁrst evident at 5months of age, localized to ONL.
(J-L) As disease progressed, α-synuclein accumulation increased in intensity, distributed throughout the inner retina. (K) Retinas of inoculated TgM83 mice are
comparable to retinas of clinically ill TgM83 mice, with α-synuclein localized to ONL and inner retina. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear
layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Insets: High magniﬁcation images of α-synuclein immunoreactivity. Scale
bars: 40 μm; insets 15 μm. (M) α-synuclein (pS129) (15 kDA), α-synuclein (15 kDA), immunoreactive bands. (N) Representative bar graph showing quantitative
densitometric analysis of α-synuclein (pS129)/α-synuclein± SD **P < 0.01 vs. B6C3H and TgM83 (5m); ***P < 0.001 vs. B6C3H and TgM83 (5m).
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Fig. 4. Accumulation of phosphorylated tau. (A, D) No pTauThr231 immunoreactivity was detectable in retinas of control mice. (B) pTauThr231 immunoreactivity was
ﬁrst appreciable in retinas of transgenic mice at 5 months of age, localized to OPL and GCL. (C, E, F) Perinuclear pTauThr231 accumulation is increased as disease
progressed. (C) pTauThr231 in retinas of inoculated TgM83 mice was comparable to retinas of TgM83 mice at clinical stage of disease. (G) Bar graphs show percent
area of ﬂuorescence for pTauThr231. Data are expressed as mean ± SD. (H-M) Confocal microscopy shows colocalization of GFAP and AT180 and of calbindin and
AT180, suggesting that tau (pThr231) is present in Müller glial processes, and calbindin immunoreactive horizontal cells and photoreceptor cell terminals, re-
spectively. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Inset:
High magniﬁcation image of perinuclear pTauThr231 localized in GCL. Scale bars: A-F 25 μm; H-M 15 μm; C inset 5 μm. ****P < 0.0001 versus B6C3H (5m);
+P < 0.05 versus B6C3H (8m); ++++P < 0.0001 versus B6C3H (8m); ‡ ‡P < 0.01; ‡ ‡ ‡ ‡ P < 0.0001.
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18m) of total area (Fig. 4G). The outer plexiform layer contains neu-
ronal processes of horizontal cells that synapse with terminal regions of
rods and cones (rod spherules and cone pedicles). Double immuno-
ﬂuorescence and confocal microscopy was used to conﬁrm colocaliza-
tion of pTauThr231 with calbindin immunoreactive processes in the outer
plexiform layer (Fig. 4H–J). Retinas of 5-month-old inoculated mice
showed colocalization of immunoﬂuorescence for calbindin and AT-180
(pThr231) in the outer plexiform layer. Since the pattern of AT-180
immunoreactivity in the outer plexiform layer was also similar to pro-
cesses of activated Müller glia, double labeling with GFAP and AT-180
was used to conﬁrm co-localization of GFAP and AT-180 in the outer
plexiform layer. Retinas of 5-month-old inoculated mice had colocali-
zation of immunoﬂuorescence for GFAP and AT-180 (pThr231) in the
outer plexiform layer. This data describes accumulation of phosphory-
lated tau in processes of neurons and retinal Müller glia, ﬁrst detected
at 5months of age. This was coincident with the ﬁrst detection of
pSer129 in retinas of 5-month-old transgenic mice. Parallel to pSer129
immunoreactivity, pTauThr231 was upregulated at 8months and in
clinically ill mice. Finally, we show signiﬁcant upregulation of
pTauThr231 immunoreactivity in retinas of inoculated mice, compared to
retinas of non-inoculated, suggesting accelerated tau phosphorylation
in response to α-synuclein seeding.
3.4. Microglial activation parallels retinal degeneration due to
accumulation of pSer129
To assess microglial activation, we performed im-
munohistochemistry using antibodies against CD11b and CD68.
Upregulation of CD11b, the β-integrin marker of microglia, and mac-
rophage antigen CD68 is associated with microglial activation in neu-
roinﬂammation (Crain et al. 2013; Roy et al. 2006; Walker and Lue
2015). In retinas of control mice, CD11b immunoreactive microglia had
small somata with thin processes, sparsely dispersed through the outer
and inner plexiform layers (Fig. 5A, D). CD11b immunoreactivity in
retinas of 5- and 8-month-old control mice occupied 0.23 ± 0.03% and
0.20 ± 0.03% of total area, respectively (Fig. 5A, D, G). Compared to
control retinas, CD11b immunoreactivity of transgenic mice at
5months of age occupied 0.68 ± 0.06% of total area (Fig. 5A, B, G).
Activated microglia were detected ﬁrst in retinas of 8-month-old mice,
shown by an increase in CD11b immunoreactivity and a change to an
amoeboid like morphology (Fig. 5D, E). Retinas of inoculated 5-month-
old mice, and clinically ill mice had signiﬁcantly upregulated CD11b
immunoreactivity, with large microglia often detected in the photo-
receptor cell layer and outer segments (Fig. C, F). CD11b im-
munoreactivity occupied 1.05 ± 0.06%, and 1.48 ± 0.203%, and
1.67 ± 0.03% of total area, respectively (Figs. 5G). A similar trend was
observed in CD68 immunoreactivity, with activated and phagocytic
microglia localized to the inner retina of transgenic mice (Fig. 5H–N).
Similar to CD11b, upregulated CD68 immunoreactivity was ﬁrst evi-
dent in retinas of 8-month-old transgenic mice, occupying
1.35 ± 0.30% of total area (Fig. 5K, L). CD68 immunoreactivity was
similar in retinas of clinically ill mice and those inoculated with brain
homogenate, occupying 2.45 ± 0.01% and 2.31 ± 0.03% of total
area, respectively (Fig. 5J, M, N). Results showed accelerated activation
of CD11b+/CD68+ microglia in retinas of 5-month-old inoculated
mice, similar to microglial activation seen in retinas of clinically ill
mice.
3.5. Dysregulation in retinal autophagy due to an increase in misfolded
proteins
To assess the eﬀect of accumulation of misfolded proteins on au-
tophagy in the retina, we performed western blot and im-
munohistochemical analyses of proteins involved in initiation of au-
tophagy and vesicle formation (Fig. 6A). In Parkinson's disease, an
increase in autophagy is a proper response during clearing of bulk cy-
toplasmic contents, such as intracellular α-synuclein, however a de-
crease below basal levels indicates autophagic dysfunction (Klionsky
et al. 2016; Lynch-Day et al. 2012). Conversely, a sustained increase of
autophagosomes may also indicate an overload of a system that is in-
capable of clearing unwanted proteins (Klionsky et al. 2016; Lynch-Day
et al. 2012). To determine changes in the initiation of autophagy, we
examined the activation status of major autophagy-initiation proteins,
pAMPKT172 and pULK1S757, by western blot analysis. There was sig-
niﬁcant upregulation of pAMPKT172 protein levels in retinas of 5-
month-old and 8-month-old transgenic mice, and a trending decrease in
retinas of 5-month-old inoculated and clinically ill transgenic mice as
compared to retinas of control B6C3H mice (Fig. 6B, C). Inversely,
pULK1S757 protein levels were signiﬁcantly lower in retinas of 5-month-
old and 8-month-old transgenic mice, however they were upregulated
in retinas of 5-month-old inoculated and clinically ill transgenic mice
(Fig. 6B, D). To assess vesicle formation, we conducted western blot
analysis and immunohistochemistry of autophagosome marker, LC3.
Similar to pAMPKT172 protein levels, LC3 II protein levels were upre-
gulated in retinas of 5-month-old and 8-month-old transgenic mice and
downregulated in retinas of 5-month-old inoculated and clinically ill
transgenic mice, compared to retinas of control mice (Fig. 6B, E). Im-
munohistochemistry results showed diﬀuse LC3 immunoreactivity in
the outer and inner retina, suggesting an active basal level of autophagy
ongoing under normal conditions (Fig. 6F). In retinas of 5-month-old
transgenic mice, we saw signiﬁcantly more LC3-immunoreactive au-
tophagosomes, primarily localized to the outer nuclear layer and outer
plexiform layer (Fig. 6G). In retinas of inoculated 5-month-old mice, we
saw depletion of LC3 throughout the entire retina (Fig. 6H–J). This was
similar to what was seen in retinas of 8-month-old and clinically ill mice
(Fig. 6H, I). Taken together, these results show changes in macro-
autophagy associated with increased accumulation of pSer129 detected
at clinical illness, or due to α-synuclein seeding. At earlier timepoints,
there was an increase in autophagic activity, suggested by the increase
in pAMPKT172 and LC3 II, and a decrease in pULK1S757. However, in
retinas of clinically ill mice and inoculated mice seeded with α-synu-
clein, we see autophagy similar to that of control mice, which suggests
that an overloading of the autophagic system, by excessive α-synuclein
accumulation, may lead to its ultimate dysfunction.
3.6. Photoreceptor cell death in α-synuclein associated retinopathy
To determine if there was photoreceptor cell loss, we assessed the
thickness of the outer nuclear layer, as measured by number of pho-
toreceptor cell nuclei. The mean thickness of the outer nuclear layer of
Fig. 5. Microglial activation. (A, B) Microglia of B6C3H and TgM83 (5m) are quiescent, with long processes and small cell bodies, localized primarily to the
plexiform layers. (C-F) Robust microglial activation is evident in retinas of TgM83 mice (8m, inoculated, and clinical). Activated microglia have large cell bodies,
thick or retracted processes, and appear to invade nuclear layers, and the outer segments of photoreceptor cells. (H-M) CD68 immunoreactivity shows activated and
phagocytic microglia localized to the inner retina, compared to the lack of activated microglia in control retinas. (J, M). Microglial activation in inoculated TgM83
mice seems accelerated, as it is comparable to that of clinical disease. (G, N) Bar graphs show percent area of ﬂuorescence for CD11b and CD68. Data are expressed as
mean ± SD. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Insets:
High magniﬁcation images of changes in microglial morphology due to activation. Scale bars: 20 μm; insets 5 μm. (G) ****P < 0.0001 versus B6C3H (5m);
+P < 0.05 versus B6C3H (8m); +++P < 0.001 versus B6C3H (8m); ‡ P < 0.05; ‡ ‡ ‡P < 0.001. (N) ****P < 0.0001 versus B6C3H (5m); +++P < 0.001 versus
B6C3H (8m); ‡ ‡ ‡ ‡ P < 0.0001.
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age-matched control B6C3H mice were 14.50 ± 0.22 and
13.00 ± 0.36 cell nuclei, respectively (Fig. 7A). Outer nuclear layer
thickness was comparable between 5-month-old non-inoculated and
inoculated transgenic mice, with 13.40 ± 0.40 and 13.2 ± 0.37 cell
nuclei, respectively (Fig. 7A). Photoreceptor cell loss was evident in
retinas of 8-month-old and clinically ill transgenic mice (Fig. 7A). Mean
outer nuclear layer thickness in retinas of 8-month-old transgenic mice
was 8.50 ± 0.50 cell nuclei (35% decrease compared to age-matched
control), while outer nuclear layer thickness in retinas of clinically ill
mice was 5.50 ± 0.50 cell nuclei (70% decrease compared to retinas of
control mice; Fig. 7A). Caspase-3 is an important mediator of neuronal
apoptosis and plays a pivotal role in pathologic death in the CNS due to
Parkinson's Disease. To determine if caspase-3 activation preceded
photoreceptor cell degeneration due to the A53T mutation, we used
cleaved anti-caspase-3 as an indicator of apoptosis. Retinas of B6C3H
mice had no detectable caspase-3 labeling, while those of 8-month-old
and clinically ill mice had caspase-3 immunoreactivity in both the outer
nuclear layer and outer segments of photoreceptor cells (Fig. 7B–D).
Detectable caspase-3 immunoreactivity coincided with retinal outer
nuclear layer thinning, suggesting the potential role of caspase-3 in
A53T mutation induced photoreceptor cell death.
3.7. A53T mouse model of synucleinopathy does not show changes in
retinal tyrosine hydroxylase immunoreactivity
Tyrosine hydroxylase (TH) catalyzes the formation of L-DOPA in the
biosynthesis of dopamine, therefore loss of TH activity followed by a
loss of the protein is classically contributed to dopamine deﬁciency and
phenotypic expression in PD (Joyce et al. 1997). To determine whether
TH-expressing (dopaminergic) cells in the retina were aﬀected due to
the A53T mutation, immunohistochemistry was performed using anti-
tyrosine hydroxylase. TH immunoreactivity was comparable in all re-
tinas, with approximately one to four amacrine cell bodies in the inner
nuclear layer of each retinal section and thick dendritic processes in the
IPL (Fig. 7E–J). Results showed no changes in TH-immunoreactive
amacrine cells.
3.8. Raman spectroscopic analysis can diﬀerentiate between spectral
signatures of normal and diseased retinas
To detect biochemical diﬀerences in the retinal ganglion cell layers
of healthy and diseased mice, we measured 20 spectra from 20 cells
within the ganglion cell layer of 6 groups of mice, for a total of 400
spectra from each group. Ganglion cells were used for analysis because
they are the innermost (closest to the lens) cellular layer of the retina.
The Raman spectra reﬂects the molecular make up of a speciﬁc sample,
with contributions from functional groups of major macromolecules
that make up cells, i.e., proteins, RNAs, and DNAs. Fifteen of the 20
spectra were used to train a classiﬁer, and 5 were used to test the
classiﬁer. The mean classiﬁcation accuracy± SD, was then calculated
to determine how well the classiﬁer could distinguish between two
pairs of samples (Table 1). Our data demonstrates a high classiﬁcation
accuracy between retinal ganglion cells of control (B6C3H 5months
and 8months) and transgenic mice (TgM83 5months and 8months),
89.33 ± 5.43% and 92.00 ± 4.73%, respectively. We also observed
high classiﬁcation accuracies between retinal ganglion cells of retinas
that were histologically similar [i.e. retinal ganglion cells of inoculated
5-month-old mice (Inoc. TgM83 5m) and clinically ill mice (TgM83
clinical) were accurately distinguishable 75.00 ± 3.23% of the time,
and retinal ganglion cells of 8-month-old mice (TgM83 8m) and
clinically ill mice were accurately distinguishable 90.00 ± 6.0% of the
time]. The lowest classiﬁcation accuracy (75.00 ± 3.23%) was ob-
served when comparing tissues that were the most histologically si-
milar, speciﬁcally retinas of clinically ill and inoculated mice. These
results suggest that Raman spectroscopy can eﬀectively discriminate
between retinal ganglion cells of healthy and diseased mice and is
sensitive enough to diﬀerentiate between retinas that are otherwise
histologically indistinguishable when analyzing α-synuclein im-
munoreactivity, pTauThr231 immunoreactivity, and microglial activa-
tion.
4. Discussion
4.1. Accumulation of pSer129 is accelerated in retinas of seeded mice
Our results demonstrate that pSer129, the principal protein mod-
iﬁcation in α-synuclein critical in the pathogenesis of Parkinson's dis-
ease, is expressed widely in retinas of transgenic mice (TgM83). In
human patients, the earliest report of α-synuclein accumulation in the
retina describes α-synuclein aggregates localized to the inner retina of
postmortem PD patients (Bodis-Wollner et al. 2014). Additionally, a
live imaging study revealed accumulation of α-synuclein deposits in
retinal ganglion cells of α-synuclein::GFP mice in a model of Parkinson's
disease (Price et al. 2016). A recent study described accumulation of
phosphorylated α-synuclein deposits in the inner retina of human PD
and Lewy body disease subjects, similar to Lewy bodies and Lewy
neurites that occur in the brain (Ortuño-Lizarán et al. 2018). Our work
describes outer and inner retinal accumulation of pSer129 due to the α-
synuclein (A53T) gene mutation, which has not yet been reported in
humans. We see detectable accumulation of pSer129 at 5months of age,
localized to the photoreceptor cell layer. Accumulation of pSer129 in
the inner retina is detected in clinically ill mice and 5-month-old mice
seeded with α-synuclein. Similar localization is observed with total α-
synuclein, detected at 5months of age in the photoreceptor cell layer,
then in the inner retina at 8months of age. Our results also show that
seeding accelerates the disease process in the retina, as the pattern and
magnitude of pSer129 protein accumulation was almost indistinguish-
able between inoculated 5-month-old mice and clinically ill mice. To
gauge the eﬀects of injection-related neuroinﬂammation, several stu-
dies report that inoculation of brain homogenate from healthy TgM83
mice fails to accelerate synucleinopathy (Luk et al. 2012b; Mougenot
et al. 2012; Sargent et al. 2017).
We show, for the ﬁrst time, that inoculation of brain homogenate of
aﬀected mice into young transgenic mice causes a prominent accel-
eration of retinal pSer129 accumulation, consistent with a “prion-like”
propagation of α-synuclein highlighted in many works (Angot et al.
2010; Katorcha et al. 2017; Luk et al. 2012a; Masuda-Suzukake et al.
2013; Mougenot et al. 2012; Woerman et al. 2017). Mougenot et al.
report accumulation of diﬀuse α-synuclein (pSer129) inclusions in
brains of TgM83 mice inoculated with brain homogenates from
Fig. 6. Dysregulation of autophagy. (A) Schematic diagram of autophagic progression, broken down into the general stages, including induction, autophagosome
formation, and degradation. (B) Western blot analysis of pAMPKT172, pULK1S757, and LC3 expression levels in the retina. pAMPKT172 (64 kDA), AMPK (64 kDA),
pULK1S757 (150 kDA), ULK1 (150 kDA), and LC3 (14,16 kDA) immunoreactive bands. (C-E) Representative bar graphs showing quantitative densitometric analysis of
pAMPKT172/AMPK±SD (I); pULK1S757/ULK1 ± SD (J); LC3 II/total protein± SD (K) in retinas of all mice. *P < 0.05; **P < 0.01; ****P < 0.0001. (F) Diﬀuse
LC3 immunoreactivity in retinas of control mice is representative of basal autophagy (G) Increase in LC3-immunoreactive autophagosomes in ONL and OPL evident
in retinas of TgM83 (5m) mice is suggestive of normal autophagic response to disease. (H-J) Retinas of TgM83 (8m), Inoculated TgM83 (5m), and clinically ill mice
show an appreciable decrease in LC3-immunoreactive puncta, similar to control retinas with basal autophagy. Abbreviations: GCL, ganglion cell layer; INL, inner
nuclear layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bars: 40 μm. Data are expressed as means± SD. *P < .05 versus
B6C3H (5m); ++++P < .0001 versus B6C3H (8m); ‡P < .05; ‡ ‡ ‡ ‡ P < .0001.
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Table 1
Mean classiﬁcation accuracies± SD for retinal ganglion cells between a paired set of samples.
TgM83 5m TgM83 8m Inoc. TgM83 5m B6C3H 5m B6C3H 8m
TgM83 8m 88.00 ± 3.50%
Inoc. TgM83 5m 89.56 ± 2.64% 89.71 ± 2.91%
B6C3H 5m 89.33 ± 5.43% 88.86 ± 6.32% 90.00 ± 4.22%
B6C3H 8m 91.71 ± 3.49% 92.00 ± 4.73% 93.67 ± 2.77% 83.50 ± 5.02%
TgM83 clinical 94.57 ± 4.86% 90.00 ± 6.00% 75.00 ± 3.23% 90.33 ± 3.48% 89.00 ± 3.00%
Fig. 7. Neuronal loss. (A) A53T mutation causes progressive photoreceptor cell death evident ﬁrst at 8months of age. Photoreceptor cell loss is also evident in retinas
of inoculated TgM83 (5m). (B-D) No caspase-3 labeling is seen in retinas of B6C3H mice, while caspase-3 immunoreactive photoreceptor cells are evident in retinas
of 8-month-old and clinically ill mice, indicating apoptotic cell death. (E-J) Tyrosine hydroxylase immunoreactivity was comparable among all mouse groups.
Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bars: 40 μm.
Data are expressed as means± SD. *P < .05 versus B6C3H (5m); ++++P < .0001 versus B6C3H (8m); ‡P < .05; ‡ ‡ ‡ ‡ P < .0001.
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clinically ill TgM83 mice, as well as early occurrence of clinical signs
and smaller survival times (Mougenot et al. 2012). An increasing
amount of in vitro and in vivo evidence argues that neurodegenerative
diseases, including Parkinson's disease, Alzheimer's disease, multiple
system atrophy (MSA), and progressive supranuclear palsy (PSP), are in
fact prion-like diseases, in which misfolded proteins (e.g. α-synuclein
and tau) undergo self-propagation. Although, it is important to note
that for example, α-synuclein prions in PD are distinct from prions in
other synucleinopathies (Luk et al. 2012a; Prusiner et al. 2015;
Woerman et al. 2016; Woerman et al. 2015; Woerman et al. 2017),
therefore may behave diﬀerently depending on disease.
4.2. Microglial and Müller glial activation diﬀers in response to α-synuclein
seeding
The ﬁrst detection of pSer129 in the retina was accompanied by up-
regulation of GFAP in Müller glia, perhaps an early indicator of retinal
stress in response to the presence of α-synuclein. GFAP im-
munoreactivity was signiﬁcantly higher in retinas of 8-month-old and
clinically ill mice, and parallel to increased pSer129 accumulation at
those time points. Activation of Müller glia is a ubiquitous response
observed in many retinal diseases (Bringmann and Reichenbach 2001),
however this observation has not been previously reported in α-synu-
clein related retinopathy. Consistent with these results, we have pre-
viously described activation of Müller glia that was coincident with the
earliest detection of retinal misfolded prion protein in a mouse model of
misfolded protein transport and accumulation (Greenlee et al. 2016).
Interestingly, GFAP immunoreactivity in retinas of 5-month-old in-
oculated mice and age-matched non-inoculated mice were comparable,
suggesting that α-synuclein “seeding” did not have a detectable eﬀect
on activation of Müller glia. However, altered microglial morphology
and retinal neuroinﬂammation demonstrated by the microglia speciﬁc
markers, CD11b and CD68, were better indicators of disease accelera-
tion. A signiﬁcant increase in CD11b immunoreactivity was ﬁrst de-
tected in retinas of 8-month-old transgenic mice, concurrent with ro-
bust CD68 immunoreactivity localized to the outer and inner retina.
Both CD11b and CD68 immunoreactivity was higher in retinas of
clinically ill mice and retinas of 5-month-old inoculated mice, sug-
gesting acceleration of retinal neuroinﬂammation in response to α-sy-
nuclein accumulation. These results were also supported by changes in
microglial morphology. We observed reactive microglia with large cell
bodies and retracted processes with an amoeboid like appearance in
retinas of clinically-ill and 5-month-old inoculated mice, while retinas
of non-inoculated 5-month-old mice had microglia with small cell
bodies and long bipolar processes indicative of a ramiﬁed, non-acti-
vated state. The contribution of microglia-mediated neuroinﬂammation
to retinal degenerative diseases is widely known (Madeira et al. 2015),
however our work describes dynamic changes in cell surface markers
and morphology of microglia in response to α-synuclein accumulation
that has not been previously reported in the retina. Numerous studies
using transgenic α-synuclein animal models link α-synuclein exposure
to MHCII-dependent microglia-mediated neuroinﬂammation, including
inﬂammatory cytokine release, increased oxidative and nitrosative
stress, and subsequent dopaminergic cell death (Schapansky et al. 2015;
Sekiyama et al. 2012). Although chronic microglial activation is a
detrimental contributor to neurodegenerative diseases, such as Par-
kinson's disease and Alzheimer's disease (reviewed in (Polazzi and
Monti 2010)), clearance and degradation of α-synuclein is a pivotal
measure taken by microglia to not only prevent the spread of α-synu-
clein, but perhaps actively avert α-synuclein internalization and de-
position into neurons (Lee et al. 2008; Rey et al. 2013). Acceleration of
microglial activation in seeded mice may correspond to the phagocytic
nature and superior scavenging capabilities of microglia that are absent
in Mϋller glia, suggesting that microglial activation may be a more
sensitive indicator of retinal disease progression.
4.3. Increased accumulation of pTauThr231 in the retina coincides with
accumulation of pSer129
A hallmark feature of neurodegenerative diseases, including
Parkinson's disease (PD) and Alzheimer's disease (AD), is the accumu-
lation of hyper-phosphorylated tau in the form of neuroﬁbrillary tan-
gles in both neurons and glial cells (Lee et al. 2001). One study de-
scribed pTauThr231 accumulation in retinal ganglion cells in a mouse
model of Alzheimer's disease (AD), suggesting a prominent role for
aberrant tau in retinal neuron dysfunction and visual defects experi-
enced by patients (Chiasseu et al. 2017). We have previously reported
the accumulation of pTauThr231 in retinal neurons and glia in a mouse
model of traumatic brain injury (Mammadova et al. 2017). Elevated
levels of hyperphosphorylated tau have been previously reported in the
striata of adult A53T mutant mice (Oaks et al. 2013; Wills et al. 2011).
Another study described the colocalization of tau oligomers with as-
trocytes and microglia in retinas of Alzheimer's disease (AD) and
frontotemporal lobar dementia (FTLD) patients, suggesting a detri-
mental relationship between the spread of tau oligomers and neuroin-
ﬂammation (Nilson et al. 2017). Thus far, the accumulation of tau in
the retina has not been described in a model of Parkinson's disease.
Our work demonstrates p-tauThr231 accumulation in processes of
retinal neurons and Mϋller glia, appreciable at 5months of age.
Phosphorylation of tau on Thr231, described as “pre-tangle” tau, has
been shown to inhibit tau's ability to bind and stabilize microtubules
(Cho and Johnson 2004). Interestingly, the ﬁrst detection of phos-
phorylated tau coincides with the ﬁrst detection of α-synuclein
(pSer129). Just as with pSer129, we see signiﬁcantly higher pTauThr231
immunoreactivity in retinas of inoculated mice, suggesting accelerated
accumulation of phosphorylated tau in response to α-synuclein seeding.
The role of tau in the pathogenesis of PD is presently unknown, how-
ever evidence suggests a stimulatory eﬀect of α-synuclein on tau
phosphorylation (Kawakami et al. 2011). Due to the co-occurrence of
tau and α-synuclein ﬁlamentous amyloid inclusions in human neuro-
degenerative diseases, in-vivo studies suggest that the interaction be-
tween α-synuclein and tau is synergistic and can promote hyper-phos-
phorylation and ﬁbrillization in the TgM83 mouse model (Giasson et al.
2003). Studies propose that the interaction between α-synuclein and
tau leads to speciﬁc and sequential phosphorylation events of the tau
protein resulting in loss of function (decreased microtubule binding), as
well as gain of function (abnormal tau-tau interactions), leading to tau
dysfunction and accumulation into neuroﬁbrillary tangles (Binder et al.
1985; de Calignon et al. 2012; Johnson and Stoothoﬀ 2004; Lei et al.
2010). Moreover, an in vitro study demonstrates that misfolded α-sy-
nuclein displays a self-replicating, as well as a cross-seeding ability (i.e.
aggregated α-synuclein can trigger misfolding of cellular prion protein)
(Katorcha et al. 2017). Another in-vitro study reports that tau ﬁbrils can
induce intracellular tangle-like aggregates, suggesting seeding activity
of misfolded tau as a potential mechanism of tau propagation in vivo
(Guo and Lee 2011).
Our work is the ﬁrst to describe accumulation of “pre-tangle” tau in
retinal neurons and glia, due to the A53T α-synuclein gene mutation.
Also, this work provides evidence that α-synuclein seeding may con-
tribute to, and possibly accelerate the accumulation of pTauThr231
proteins in the retina. Although compelling, the mechanisms underlying
the interaction of α-synuclein (pSer129) and tau require further in-
vestigation.
4.4. A decrease in autophagy is coincident with increased accumulation of
α-synuclein, and pTauThr231
This work describes changes in retinal macroautophagy associated
with the pathogenic A53T mutant α-synuclein, that have not been
previously reported. Macroautophagy is the only known intracellular
mechanism potentially capable of degrading bulk protein aggregates,
although in mammals, all of the proteins involved and the precise
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sequence of events are still not completely established (reviewed in
(Jaeger and Wyss-Coray 2009)). Brieﬂy illustrated in Fig. 6, the in-
itiation stage involves activation of ULK1 (a serine-threonine kinase),
regulated by both mTOR and AMPK. Activation of mTOR leads to the
enzymatic inactivation of ULK1, by downstream phosphorylation at
serine 757. Conversely, when AMPK is activated by phosphorylation at
Threonine 172 and mTOR is inhibited, due to nutrient deﬁcit or stress,
ULK1 is dephosphorylated at Serine 757 and thereby activated allowing
for autophagy to progress. Subsequently, lipidation of LC3 I to form LC3
II, and binding of speciﬁc adaptor proteins such as p62, contributes to
autophagosome formation. Finally, fully formed autophagosomes fuse
with lysosomes for degradation and recycling of cellular contents in-
cluding organelles and proteins. Our results demonstrate two opposing
events in the autophagic pathway: upregulation of the initiation of
autophagy, suggested by the increase in pAMPKT172 and LC3 II, along
with the decrease in pULK1S757 at “early” timepoints (retinas of 5-
month-old and 8months old mice); downregulation of autophagy at the
“later” timepoint (retinas of clinically ill mice). Retinas of inoculated or
“seeded” mice were almost indistinguishable from those of clinically ill
mice, perhaps suggesting impaired autophagy due to an overload of the
system by misfolded α-synuclein accumulation. Here, the upregulation
event ﬁrst detected in retinas of 5-month-old transgenic mice, coincides
with the ﬁrst detection of pSer129 and pTauThr231 accumulation, a
proper response during clearing of cytoplasmic contents. Later, down-
regulation of autophagy seen in retinas of clinically ill and seeded mice,
could suggest impaired autophagy due to an overload of misfolded
proteins, α-synuclein and pTauThr231. In neurodegenerative diseases
such as PD, AD, and Huntington's disease, autophagy is impaired (re-
viewed in (Jaeger and Wyss-Coray 2009)). Consistent with our results,
the general hallmark eﬀect of CNS disease on autophagy is the accu-
mulation of autophagosome-like structures. However, whether autop-
hagosome accumulation occurs due to an impairment in the degrada-
tion of autophagosomes, or due to an increased need for the clearance
of unwanted intracellular contents, is not yet known. Speciﬁcally, in PD
associated mutations A53T and A30P, a study demonstrated that α-
synuclein inhibits chaperone-mediated autophagy (CMA) by binding to
its receptor and preventing not only degradation of itself, but that of
other autophagy substrates (Cuervo et al. 2004). It is also unknown
whether abnormalities in the autophagy pathway are caused by mutant
or misfolded proteins, or whether deﬁcits in the degradation of mis-
folded proteins are yet another factor that leads to protein aggregation.
The complex intricacies of the autophagic pathway in neurodegenera-
tive diseases are far from being understood, however data presented in
this study suggests it may play a role in the cellular response to mis-
folded proteins including α-synuclein (pSer129) and pTauThr231.
4.5. Loss of retinal neurons in α-synuclein associated disease
This study reports loss of photoreceptors ﬁrst detected in retinas of
8-month-old transgenic mice, corresponding to widespread distribution
of pSer129 in the outer nuclear layer. The ﬁrst detection of pSer129
immunoreactivity in retinas of 5-month-old mice precedes retinal
thinning detected in retinas of 8-month-old mice. This observation is
supported by studies that demonstrate an increase in misfolded proteins
before onset of pathological changes (Sandberg et al. 2014). Loss of
photoreceptors also coincided with cleaved caspase-3 im-
munoreactivity, detectable in the outer nuclear layer and the outer
segments of photoreceptor cells, which may suggest photoreceptor
apoptosis. Photoreceptor cell loss in response to the accumulation of
misfolded proteins has been previously reported in a seeded rodent
model of scrapie, and similar to our observation, loss of retinal neurons
did not occur until late in the disease long after the ﬁrst detection of
misfolded prion protein (Greenlee et al. 2016). Besides scrapie, the
vulnerability of photoreceptor cells to the accumulation of misfolded
proteins has also been shown in other models of transmissible spongi-
form encephalopathies (TSEs), including Creutzfeldt-Jacob disease
(Hogan et al. 1983) and transmissible mink encephalopathy (Hogan
et al. 1986), however photoreceptor cell death in response to α-synu-
clein accumulation has not been previously reported. Visual deﬁcits in
PD are often attributed to dopaminergic deﬁciency (Archibald et al.
2009), however our results demonstrate no detectable changes in tyr-
osine hydroxylase immunoreactivity in dopaminergic amacrine cells.
While there is evidence of reduced tyrosine hydroxylase im-
munoreactivity in retinas of PD patients, this observation was made in
ﬁve patients and has not been since examined (Nguyen-Legros 1988).
Retinal dopamine deﬁciency in PD has not been since explored. Further
studies are necessary to delineate the eﬀect of α-synuclein on retinal
dopamine, and whether this contributes to visual dysfunction in PD.
4.6. Raman spectroscopy can detect molecular changes in Parkinson's
disease related retinopathy
In this study, we explored the potential of using Raman spectro-
scopy for diﬀerentiating retinal tissues of transgenic mice from those of
healthy controls. Since our histological data demonstrated pathologic
changes in retinas of transgenic mice, it was reasonable to hypothesize
a diﬀerence in the molecular makeup of aﬀected ganglion cells. For the
ﬁrst time in this study, spectroscopic markers associated with changes
in α-synuclein related intracellular protein compositions in retinal
ganglion cells were identiﬁed with high accuracy. Raman spectroscopy
has been an invaluable tool facilitating several biomedical applications,
including diagnostics and therapeutic development. For example,
Raman spectroscopy is slowly making its way into clinics as a non-in-
vasive way to characterize diﬀerent cancers, by collecting biochemical
information from in situ samples of tumors (Huang et al. 2005; Taleb
et al. 2006). Raman spectroscopy has also been successfully used for the
evaluation of glaucomatous retinal changes in canine tissues (Wang
et al. 2011). Taken together with our results, Raman spectroscopic
screening could potentially be used for early characterization of pa-
thologic retinal changes due to a variety of neurodegenerative dis-
orders. If further optimized and reﬁned, and in combination with in
vivo imaging techniques, Raman spectroscopy may be implemented to
develop eﬀective and safe early-diagnostic modalities for PD patients
with deﬁcits in vision.
5. Conclusions
In this study, we report retinal changes associated with the α-sy-
nuclein A53T mutation, as well as describe the eﬀect of α-synuclein
“seeding” on the development of retinal pathology. We demonstrate
that pSer129 is ﬁrst detected in retinas of transgenic mice at 5months
of age, then widely expressed in the outer and inner retina. This ﬁnding
is consistent with the ﬁrst detection of pTauThr231, and activation of
retinal Mϋller glia and microglia. We report that microglial activation
seems to be a more sensitive indicator of retinal stress, as we see a
robust increase in microglial activation, but not activation of Müller
glia, due to seeding. We show, for the ﬁrst time, that seeding with brain
homogenate from clinically ill mice, causes a prominent acceleration of
retinal pSer129 and pTauThr231 accumulation. This ﬁnding is consistent
with other works describing the self-propagating ability of misfolded
proteins. Our work also suggests that seeding with brain homogenate
from clinically ill mice leads to the dysfunction of protein degradation,
and collapse of protein quality control systems leading to neuroin-
ﬂammation and further accumulation of misfolded proteins. An in-
crease in pSer129 and pTauThr231 accumulation may lead to dysregu-
lation in retinal autophagy and cell death, however mechanistic studies
are necessary to delineate direct eﬀect of prion-like α-synuclein pro-
pagation from the detrimental eﬀects of general cellular dysfunction
speciﬁc to protein degradation. Finally, we provide evidence that
Raman spectroscopy can be used to diﬀerentiate between retinal tissues
from control, healthy, and diseased mice with high accuracy, even
among retinas that appear histologically similar. If further reﬁned,
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successful implementation of this non-invasive and rapid technique can
potentially replace histology as the current gold standard of synuclei-
nopathy diagnosis, perhaps earlier in the disease process than is cur-
rently possible. Taken together, our work sheds light on the patholo-
gical events of Parkinson's disease in the retina that have not been
previously reported.
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